They’re in our blood and our brains. They’re in newborns and the elderly, urban and rural, rich and poor. What are they doing ...

WEIGHT loss jabs could raise the risk of a “potentially blinding condition” known as an “eye stroke”, researchers have warned ...

ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)——FY 2025 ORLADEYO ...

The initialism was originally a bit of shipbuilder marketing—and now there are many different kinds of ship designations.

Nearly a dozen miles off the California coast on a foggy October morning, a crane lifts a boxy yellow robot off the deck of the research vessel Rachel ... are organisms labeled by the AI or ...

In September, the Nigerian government made an important change to its food fortification program to date—a set of standards ...

On January 1, 2025, new regulations governing Proposition 65’s so-called safe-harbor warnings went into effect. Proposition ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

New research provides further evidence that thrombolysis benefits select patients with acute ischemic stroke up to 24 hours after symptom onset.

IntroductionThe evolution of packaging from ancient times to modernity reflects not only technological advances but also the recognition of its critical role in preserving and presenting many products ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)- -FY 2025 ORLADEYO net revenue guidance increased to between $535-$550 mil ...